This seems like great practice, despite being extraordinarily fraught with difficult decisions. If we attempt a custom solution to hundreds or thousands of thes

This seems like great practice, despite being extraordinarily fraught with difficult decisions. If we attempt a custom solution to hundreds or thousands of these rapidly dying patients, we may learn a tremendous amount about each disease we attempt to treat. If we don't make strides on the diseases, we will at least learn to quickly iterate on drug manufacturing. The quoted 7000 rare diseases won't be solved with traditional investment in each one. It seems reasonable that we attempt alternative techniques and learn from each attempt. I worry about two things: That we will use custom drugs when traditional techniques would be more effective, and that money that would otherwise be effectively spent on traditional research is spent on the custom drug effort.